The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.
M. M. Javle
No relevant relationships to disclose
G. R. Varadhachary
No relevant relationships to disclose
D. R. Fogelman
No relevant relationships to disclose
R. T. Shroff
No relevant relationships to disclose
M. J. Overman
No relevant relationships to disclose
L. Ukegbu
No relevant relationships to disclose
B. N. Bekele
No relevant relationships to disclose
S. P. Kar
No relevant relationships to disclose
R. A. Wolff
No relevant relationships to disclose
J. L. Abbruzzese
No relevant relationships to disclose